This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revisionNext revision | Previous revisionNext revisionBoth sides next revision | ||
home:protocol:olmesartan [02.25.2019] – [Kidney disease] sallieq | home:protocol:olmesartan [03.30.2020] – [Cardiovascular disease] sallieq | ||
---|---|---|---|
Line 1: | Line 1: | ||
====== Science behind olmesartan (Benicar) | ====== Science behind olmesartan (Benicar) | ||
+ | |||
+ | |||
+ | < | ||
Patients on the [[home: | Patients on the [[home: | ||
Line 123: | Line 126: | ||
* inhibit liver fibrosis and aid liver healing(({{pubmed> | * inhibit liver fibrosis and aid liver healing(({{pubmed> | ||
* reduce insulin resistance in rats(({{pubmed> | * reduce insulin resistance in rats(({{pubmed> | ||
- | * 6 mg/kg olmesartan reduces the inflammatory process and bone loss in rats(({{pubmed> | + | * 6 mg/kg olmesartan reduces the inflammatory process and periodontal |
* protect the mitochondria from age-associated damage from oxidation(({{pubmed> | * protect the mitochondria from age-associated damage from oxidation(({{pubmed> | ||
* play a protective role against proliferative diabetic retinopathy (({{pubmed> | * play a protective role against proliferative diabetic retinopathy (({{pubmed> | ||
Line 133: | Line 137: | ||
==== Cardiovascular disease ==== | ==== Cardiovascular disease ==== | ||
+ | |||
< | < | ||
Line 200: | Line 205: | ||
- | {{tag> | + | {{tag> |
===== Notes and comments ===== | ===== Notes and comments ===== | ||